Visão geral da empresa
A fully integrated biopharmaceutical entity, Tonix Pharmaceuticals Holding Corp. focuses on the development and commercialization of therapies targeting central nervous system disorders, immunology, immuno-oncology, infectious diseases, and rare diseases within the United States market. The company operates within the healthcare sector and specifically functions in the biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory hurdles for product approval. Its current market capitalization stands at $185.24M, supported by an annual revenue of $13.11M and a workforce comprising 142 employees. These valuation and revenue figures indicate that Tonix is a small-cap biotechnology firm with a limited revenue base relative to its market capitalization, suggesting that the market price reflects expectations of future value creation rather than current cash generation. The disparity between its market cap and revenue highlights the speculative nature often associated with companies in the early stages of commercializing novel therapies for specialized medical conditions.
Saúde financeira
Tonix Pharmaceuticals reported a revenue of $13.11M over the trailing twelve months, yet this figure contrasts sharply with a net income loss of $-124,021,000 and an EBITDA of $-123,778,000. The substantial gap between the positive revenue and the deep negative net income reveals a cost structure where operating expenses, likely driven by research and development or commercialization costs, significantly exceed total sales, resulting in a loss of nearly ten times the revenue generated. The company's free cash flow stands at $-59,429,000, which indicates a consumption of cash reserves rather than cash generation, thereby limiting immediate financial flexibility and increasing reliance on external capital sources or existing cash balances to fund operations. Margin analysis shows a gross margin of 49.3%, suggesting efficient production costs for its products, but this is overwhelmed by an operating margin of -895.8% and a profit margin of 0.0%, reflecting the intense expense burden typical of biotechnology firms before achieving commercial scalability. Regarding liquidity and leverage, the company holds $207.64M in cash against a negligible debt level of $1.31M, supported by a debt-to-equity ratio of 0.53, which suggests a balance sheet that is highly conservative regarding leverage despite the losses. This strong cash position is further evidenced by a current ratio of 7.42, indicating that the company possesses more than seven times the current assets necessary to cover its short-term liabilities, providing a robust buffer against immediate solvency risks. However, the return on equity is -64.5% and the return on assets is -35.7%, metrics that reveal that management has not yet generated positive returns on the capital invested or assets held, a common characteristic for biotech entities still in the growth phase of their lifecycle.
Avaliação de valorização
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the lack of earnings, while the Forward P/E is reported at -2.53. The divergence between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a turnaround scenario or a shift from losses to profitability in the near future, rather than valuing current earnings. The Price to Book ratio is 0.68, indicating that the market values the company at less than its book value, which often suggests a discount applied to assets that may not be easily liquidatable or that future earnings potential is viewed with skepticism. Additionally, the Price to Sales ratio is 14.13, and the EV/EBITDA is 0.26; these alternative metrics suggest that investors are willing to pay a significant premium relative to sales despite the lack of profitability, while the low EV/EBITDA reflects the heavy expense structure depressing earnings before interest, taxes, depreciation, and amortization. The stock price has experienced significant volatility, trading between a 52-week high of $69.97 and a 52-week low of $11.60. If the current price is near the lower end of this historical range, it implies the stock is trading at a discount relative to its recent peak, potentially reflecting market caution regarding the path to profitability. The Beta is 1.76, which indicates that the stock price is significantly more volatile than the broader market, moving with a magnitude 76% higher than the market index on average, a characteristic trait of smaller biotechnology companies that are sensitive to clinical trial results and regulatory news.
Growth & Income
The revenue growth year-over-year is 108.8%, while the earnings growth year-over-year is N/A due to the absence of prior period earnings. The fact that earnings growth is not available while revenue growth is robust implies that the company is in a stage where top-line expansion is the primary driver of value, as the bottom line has not yet stabilized to allow for meaningful year-over-year percentage comparisons. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that any surplus cash or potential future earnings are reinvested into research, development, and commercialization efforts rather than being distributed to shareholders. This reinvestment strategy is typical for biotechnology firms that prioritize funding new drug pipelines over providing current income to investors. The overall growth and income profile for Tonix Pharmaceuticals is defined by rapid revenue expansion funded by existing cash reserves, with no current income distribution to shareholders, reflecting a classic growth-stage biotechnology model where capital is retained to accelerate product development and market penetration.